CardioDx raises $35 million for COPD development

Subscribe via: RSS

Diagnostics, Financing

CardioDx raises $35 million for COPD development

Posted on 20 December 2014

CardioDx announced the close of $35 million in total equity financing.

Alberta Investment Management Corporation (AIMCo) participated in this round together with the company's existing investors.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

The funds will enable CardioDx to broaden the commercial use of Corus CAD, the only clinically validated blood test that uses age, sex and gene expression to measure the likelihood of obstructive coronary artery disease in symptomatic patients, as well as to augment the company's research efforts to improve healthcare quality and efficiency through the development of additional genomic tests for coronary artery disease.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog